Leen Kawas - Oct 18, 2023 Form 3 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role
10%+ Owner
Signature
/s/ Leen Kawas
Stock symbol
EIGR
Transactions as of
Oct 18, 2023
Transactions value $
$0
Form type
3
Date filed
10/30/2023, 04:51 PM
Next filing
Nov 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EIGR Common Stock 1.67M Oct 18, 2023 See footnote F1, F3
holding EIGR Common Stock 2.7M Oct 18, 2023 See footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds directly own 1,667,100 shares of Common Stock.
F2 Propel Management acts as the investment advisor to an investment company registered under the Investment Company Act of 1940, as amended, and such investment company directly owns 2,700,000 shares of Common Stock.
F3 Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.